Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06842745 · ClinicalTrials.gov registry record · Phase 2

Transcranial Magnetic Stimulation + Language Therapy to Treat Mild Aphasia

A Phase 2 study of Stroke and Aphasia, sponsored by University of Pennsylvania.

Recruiting
Registry status
Phase 2
Development phase
24
Enrollment target
1
Study location

NCT06842745: Recruiting Phase 2 study of Stroke and Aphasia, sponsored by University of Pennsylvania.

NCT06842745 is a Phase 2 study of Stroke and Aphasia that is actively recruiting participants, run by University of Pennsylvania. The registered enrollment target is 24 participants, below the 12,016-participant average among 454 other Stroke trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06842745, a Phase 2 study of Stroke and Aphasia, is actively recruiting participants, sponsored by University of Pennsylvania.

RECRUITING
Registry status
Phase 2
Development phase
24 participants
Enrollment target
1
Study location

Study Summary

The goal of this clinical trial is to determine if Transcranial Magnetic Stimulation (TMS) combined with Speech-Language Therapy (SLT) is an effective treatment for mild aphasia in persons with chronic stroke. The main questions this study aims to answer are: 1. Can TMS combined with SLT improve conversational speech and comprehension? 2. Can we identify specific behavioral and biological characteristics that would benefit most from the TMS and SLT treatment? Researchers will compare real TMS to sham (fake) TMS to see whether TMS can treat post-stroke mild aphasia. Participants will: * Complete a screening and medical intake to determine eligibility * Undergo a MRI * Participate in 10 consecutive sessions (Monday-Friday) of TMS and SLT treatment * Complete follow-up assessments 2 and 4 months after treatment

Primary Outcome

Change in performance on the Temple Assessment of Language and Short-term Memory in Aphasia (TALSA) sentence processing composite score.

Interventions

  • BEHAVIORAL Speech-Language Therapy (SLT)
  • DEVICE Transcranial Magnetic Stimulation (TMS)

Study Locations (1)

Pennsylvania

  • University of Pennsylvania - Philadelphia

Trial Details

FieldValue
Enrollment Target 24 participants
Start Date 2025-02-11
Est. Completion 2026-08-31
Phase Phase 2
University of Pennsylvania

1,423 total trials

What NCT06842745 shows while recruiting

NCT06842745 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 12,016-participant average among 454 other Stroke trials with a reported enrollment target (100% lower).

The record links to 4 conditions, with Stroke appearing as the primary indexed condition, and to 2 interventions - of which Speech-Language Therapy (SLT) is the first listed.

NCT06842745 reports a single indexed study location in Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT06842745 about?

NCT06842745 is a clinical study titled "Transcranial Magnetic Stimulation + Language Therapy to Treat Mild Aphasia". The goal of this clinical trial is to determine if Transcranial Magnetic Stimulation (TMS) combined with Speech-Language Therapy (SLT) is an effective treatment for mild aphasia in persons with chronic stroke. The main questions this study aims to answer are: 1. Can TMS combined with SLT improve c...

What is the current status of trial NCT06842745?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2025-02-11. Estimated completion is 2026-08-31.

What conditions does trial NCT06842745 study?

This clinical trial studies the following conditions: Stroke, Aphasia, Aphasia, Acquired, Aphasia Following Cerebral Infarction.

What interventions are being tested in trial NCT06842745?

The interventions under investigation include: Speech-Language Therapy (SLT) (BEHAVIORAL), Transcranial Magnetic Stimulation (TMS) (DEVICE).

Who is sponsoring clinical trial NCT06842745?

This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06842745 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Stroke

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06842745's enrollment target sits among peer trials

24 336th of 454 higher than 109 of 454 other Stroke trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Stroke trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02331979 · 24 participants · NA

    Improving Bladder Function in SCI by Neuromodulation

  • NCT03096197 · 24 participants · NA

    Exoskeleton and Spinal Cord Stimulation for SCI

  • NCT03223922 · 24 participants · NA

    Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases

  • NCT03326921 · 24 participants · Phase 1

    HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06842745, the US trial registry maintained by the National Library of Medicine. NCT06842745 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.